This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Health fund files US antitrust claims against Biogen over Tecfidera in Illinois

( September 27, 2024, 22:31 GMT | Official Statement) -- MLex Summary: The Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees’ Benefit Fund filed a US complaint accusing Biogen of unlawfully impairing competition from generic versions of its brand-name prescription drug Tecfidera, which is used to treat multiple sclerosis. According to the complaint, Biogen orchestrated a “market switch” by getting doctors to switch their prescribing from Tecfidera to a new and essentially identical version of the drug before the generic versions of Tecfidera were available in the marketplace.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections